Loading...
In Vivo Evolution of CMY-2 to CMY-33 β-Lactamase in Escherichia coli Sequence Type 131: Characterization of an Acquired Extended-Spectrum AmpC Conferring Resistance to Cefepime
Cefepime is frequently prescribed to treat infections caused by AmpC-producing Gram-negative bacteria. CMY-2 is the most common plasmid-mediated AmpC (pAmpC) β-lactamase. Unfortunately, CMY variants conferring enhanced cefepime resistance have been reported. Here, we describe the evolution of CMY-2...
Na minha lista:
| Udgivet i: | Antimicrob Agents Chemother |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society for Microbiology
2015
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4649241/ https://ncbi.nlm.nih.gov/pubmed/26392491 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01804-15 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|